Inclusion Criteria:

- Eligibility rule of enrollment

- Rectal adenocarcinoma that were 15 cm or more from the anal verge

- pathologically diagnosed stage II or III disease

- patients who meet the discharge criteria within 10days after surgery

- Patients with adequate hepatic, renal, and bone marrow function, and a left
ventricular ejection fraction of 55% or higher measured by echocardiography

Exclusion Criteria:

- An ineligibility to participate in the clinical study based on the judgment of
investigators from a legal perspective

- A past history of chemotherapy

- tumor with obstruction or perforation

- tumor with distant metastases

- synchronous tumor

- relative or absolute contraindications of chemotherapy

- Recent MI, CVA, nitrate medication

- Severe cardiovascular disease, psychiatric disease

- Severe hepatic dysfunction (GOT, GPT ≥100IU/L)

- Renal dysfunction (Cr ≥2mg/dl)

- The concurrent presence of other severe medical diseases